Expired Tender USA ICB TOT Ref. 74010086

Pfizer Paxlovid Covid-19 Therapeutic Tender in USA - 74010086

Tender notice from USA, published on 03 Nov 2022.

Executive Summary

The DEPT OF DEFENSE has issued a Tender notice for the procurement of a Pfizer Paxlovid Covid-19 Therapeutic in the USA. This Tender notice was published on 03 Nov 2022 and is scheduled to close on 09 Nov 2022, with an estimated Tender value of Refer Document. Interested bidders can access detailed Tender information, eligibility criteria, and complete bidding documents by referencing TOT Ref No. 74010086, while the tender notice number is W58P0522C0001P00005 and Register on the platform.

Key facts

Summary
Pfizer Paxlovid Covid-19 Therapeutic
TOT Ref. No.
74010086
Document Ref. No.
W58P0522C0001P00005
Country
USA
Notice type
Tender
Competition
ICB
Publication date
03 Nov 2022
Bid deadline
09 Nov 2022
EMD
Refer Document
Tender value
Refer Document
Purchaser ownership
Public
Financier
Self Financed

Purchaser details

Purchaser contact is for registered users

Login to see details

Tender details

Description
The U.S. Army Contracting Command - Joint COVID-19 Response Division, 6472 Integrity Court (Building 4401), Aberdeen Proving Ground, MD 21005-3013 has a sole source requirement on behalf of the Department of Health and Human Services (DHHS) (collectively, the Government or USG) to procure up to 3.7 million treatment courses (TC) of Pfizer-s oral antiviral therapeutic, PAXLOVID, to treat the US general population in response to the SAR-CoV-2 Virus.
This acquisition will be conducted as a sole source contract to Pfizer Inc., 235 E. 42nd St, New York, New York, 10017-5703, IAW FAR 6.302-1. The USG anticipates awarding a firm fixed price contract modification with a period of performant of 81 months. Interested parties who believe they have a basis for providing Pfizer-s oral antiviral therapeutic PAXLOVID product, or have other questions pertaining to this acquisition, may contact Danny Soto at [email protected] and Robin Bronson at [email protected]
Active Contract Opportunity

Notice ID : W58P0522C0001P00005

Related Notice

Department/Ind. Agency : DEPT OF DEFENSE

Sub-tier : DEPT OF THE ARMY :

General Information

Contract Opportunity Type: Special Notice (Original)

All Dates/Times are: (UTC-04:00) EASTERN STANDARD TIME, NEW YORK, USA

Original Published Date: Nov 02, 2022 01:28 pm EDT

Original Response Date: Nov 09, 2022 03:00 pm EST

Inactive Policy: 15 days after response date

Original Inactive Date:

Initiative: None
Classification

Original Set Aside:

Product Service Code: 6505 - DRUGS AND BIOLOGICALS

NAICS Code: 325412 - Pharmaceutical Preparation Manufacturing
Place of Performance: New York, NY 10017 USA

Documents

Tender Notice
Login to view

USA Public Procurement Intelligence

Frequently asked questions

The bid deadline for Pfizer Paxlovid Covid-19 Therapeutic was 09 Nov 2022. Bidding is closed.

This tender has been issued by DEPT OF DEFENSE in USA.

The tender value is not disclosed; please refer to the tender document. EMD / bid security details are provided in the tender document.

This tender is Self Financed

The tender notice and related documents are listed in the Documents section above. Select a document to view or download it. Please log in or register to access the documents. If you cannot find additional documents in the Documents section, please log in to your account and Send Document Request from your account section.

The TendersOnTime reference is 74010086. The purchaser document reference is W58P0522C0001P00005.

Browse other tenders from USA or search by relevant keywords and CPV classification.